Black Diamond Therapeutics Inc (NAS:BDTX)

$ 4.79 0.02 (0.42%) Market Cap: 269.52 Mil Enterprise Value: 178.87 Mil PE Ratio: 0 PB Ratio: 2.41 GF Score: 39/100

Black Diamond Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 11, 2023
Black Diamond Therapeutics Inc BDTX-1535 Interim Results Call Transcript
Jun 27, 2023
Black Diamond Therapeutics Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2023
Black Diamond Therapeutics Inc Annual Shareholders Meeting Transcript
May 16, 2023
Black Diamond Therapeutics Inc at Stifel Targeted Oncology Days (Virtual) Transcript
Apr 25, 2023
Black Diamond Therapeutics Inc at Cowen Health Care Conference Transcript
Mar 06, 2023
Black Diamond Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 12, 2023
Black Diamond Therapeutics Inc at Piper Sandler Healthcare Conference Transcript
Dec 01, 2022
Black Diamond Therapeutics Inc at Stifel Healthcare Conference Transcript
Nov 15, 2022
Black Diamond Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 07, 2022
Black Diamond Therapeutics Inc at Canaccord Genuity Horizons in Oncology Conference (Virtual) Transcript
Apr 14, 2022
Black Diamond Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 18, 2021
Black Diamond Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 12, 2021

Black Diamond Therapeutics Inc at Stifel Targeted Oncology Days (Virtual) Transcript

Apr 25, 2023 / 03:00PM GMT

Release Date Price: $1.53 (-3.16%)

Transcript 10-Q8-K

Bijan Mekoba

Stifel Financial Corp. - Moderator

Good morning, everyone. I'm Bijan Mekoba, senior research associate with Black [Diamond] here at Stifel. Welcome to our Target Oncology Days. We're excited to have the CEO of Black Diamond Therapeutics with us. David Epstein. Thank you for joining us. He'll be discussing the company's lead asset BDTX-1535 and their earlier stage pipeline.

So I'll pass it to you, David.

David Epstein

Black Diamond Therapeutics, Inc. - Co-Founder, President, CEO

Well, thank you, Bijan, and good morning, everyone, and thank you for joining. Really delighted to be here. I'll introduce the company. I just want to highlight that this company and the team has had a tremendous amount of experience, both advisers and the people actually carrying out the work in the company in the targeted therapy area. Having all collaborated on the development of Tarceva, one of the first generation EGFR inhibitors approved for the treatment of lung cancer.

I want to remind everybody that this presentation contains forward looking

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.